Guidelines for non-pharmacological and pharmacological approaches to the treatment of hypertension were issued for the first time in the middle of the 1970s and were periodically updated in the following years. This gaper will review the main features and elements of novelty of the World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension issued in 1999. After briefly describing data relating to the epidemiology of hypertension, the 1999 WHO-ISM Guidelines take into account the determinants of cardiovascular disease risk in hypertensive patients. Particular emphasis is placed on the contributions from and interactions between high blood pressure and other factors or conditions (diabetes, smoking, hypercholesterolaemia, alcohol consumption, overweight and obesity, etc) involved in determining the risk profile of individual patients. Finally, the WHO-ISM 1999 Guidelines provide recommendations for hypertension drug treatment in relation to the risk stratification and prognosis quantification, indicating the specific therapeutic strategy to be followed in each risk category.

Mancia, G., Grassi, G. (2000). World Health Organization - International Society of Hypertension Guidelines and the role of ongoing trials. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2(D), 7-10.

World Health Organization - International Society of Hypertension Guidelines and the role of ongoing trials

MANCIA, GIUSEPPE;GRASSI, GUIDO
2000

Abstract

Guidelines for non-pharmacological and pharmacological approaches to the treatment of hypertension were issued for the first time in the middle of the 1970s and were periodically updated in the following years. This gaper will review the main features and elements of novelty of the World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension issued in 1999. After briefly describing data relating to the epidemiology of hypertension, the 1999 WHO-ISM Guidelines take into account the determinants of cardiovascular disease risk in hypertensive patients. Particular emphasis is placed on the contributions from and interactions between high blood pressure and other factors or conditions (diabetes, smoking, hypercholesterolaemia, alcohol consumption, overweight and obesity, etc) involved in determining the risk profile of individual patients. Finally, the WHO-ISM 1999 Guidelines provide recommendations for hypertension drug treatment in relation to the risk stratification and prognosis quantification, indicating the specific therapeutic strategy to be followed in each risk category.
Articolo in rivista - Articolo scientifico
antihypertensive treatment; management guidelines; cardiovascular risk; drugs; clinical trials
English
mag-2000
2
D
7
10
none
Mancia, G., Grassi, G. (2000). World Health Organization - International Society of Hypertension Guidelines and the role of ongoing trials. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2(D), 7-10.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/5028
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact